<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are at high risk for <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> (CHD); frequently, these patients have abnormal <z:chebi fb="23" ids="18059">lipid</z:chebi> profiles, placing them at even greater risk </plain></SENT>
<SENT sid="1" pm="."><plain>A syndrome of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, <z:e sem="disease" ids="C0020459" disease_type="Disease or Syndrome" abbrv="">hyperinsulinaemia</z:e>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, and high levels of fibrinogen and plasminogen activator inhibitor contributes to cardiovascular risk, which is not sufficiently decreased by glycaemic control alone </plain></SENT>
<SENT sid="2" pm="."><plain>In several large interventional trials, CHD risk in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> was substantially reduced by aggressive <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering therapy </plain></SENT>
<SENT sid="3" pm="."><plain>In patients with <z:mp ids='MP_0002055'>diabetes</z:mp>, CHD, low <z:chebi fb="6" ids="39025">high-density lipoprotein</z:chebi> levels, and <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> levels, <z:chebi fb="0" ids="5296">gemfibrozil</z:chebi> reduced fatal and non-fatal CHD events </plain></SENT>
<SENT sid="4" pm="."><plain>For <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and CHD, pravastatin and <z:chebi fb="0" ids="9150">simvastatin</z:chebi> are the only <z:chebi fb="0" ids="35664">HMG-CoA reductase inhibitors</z:chebi> shown to reduce fatal and non-fatal CHD events </plain></SENT>
<SENT sid="5" pm="."><plain>Of these, pravastatin has less potential for drug-drug interactions and may be safer to use, particularly for combination therapy with fibric acid derivatives, as may now be important for CHD prevention in mixed <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemias</z:e> </plain></SENT>
</text></document>